A pharmaceutical company that develops and markets drugs targeting cortisol regulation, including Korlym for Cushing's syndrome and related pipeline candidates.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 38 | Holds (flat) | 15,588 | $542,462 | 0.0% |
| Bridgewater | 49 | Trimmed -9% | 279,000 | $9,709,200 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.